Business Wire

Allison Unveils New Brand Identity to Reflect Agency’s Evolution

6.9.2023 13:00:00 EEST | Business Wire | Press release

Share

After more than two decades of remarkable growth and evolution, Allison (fka Allison+Partners) is excited to unveil its new brand identity, complete with a new name, logo, website and visual identity. The rebranding effort reflects the agency's transformation from its origin as a traditional PR firm focused on earned media to a modern integrated marketing and communications powerhouse with a global presence.

"Today marks a significant milestone in our history,” says Scott Allison, global chairman and CEO of Allison. “The unveiling of our new brand identity represents not just a change in name and logo, but a bold declaration of our commitment to shaping the future of integrated marketing and communications. We have evolved alongside the industry, embracing innovation and expanding our global footprint. This rebranding is a testament to our team's dedication to excellence, creativity, and the relentless pursuit of solutions that drive meaningful impact for our clients. With Allison, we are poised to lead the way in a new era of communications."

Why Rebrand? Why Now?

Over the past 22 years, Allison has undergone a remarkable evolution, expanding its services, client portfolio and talent base to encompass a diverse range of expertise, from to creative solutions. The agency also saw significant growth in the number of global assignments —with seven of its top 10 clients now represented across multiple markets—and an enhanced client roster of global brands, such as AB InBev, GE Appliances, Hewlett Packard Enterprise, IHG, Kyndryl and Revlon. This rebranding initiative is a response to the need for a refreshed brand identity that aligns with the agency's current and future trajectory, while highlighting its unique culture, global reach, integrated capabilities and forward-thinking approach. Visit the new website at www.allisonworldwide.com to explore the refreshed brand identity and learn more about Allison's innovative solutions.

Solving Fragmentation and Embracing Innovation

The rebranding also aims to address the challenge of fragmentation that has naturally occurred as the agency has grown and the marketing landscape has evolved, potentially diluting or blurring the agency's points of differentiation. By simplifying and unifying the brand story, Allison will better convey its ability to solve complex business challenges, attract top talent, and provide integrated marketing and communications on a global scale. The new brand identity not only celebrates the agency's growth but also positions it as a driver of the industry's future innovations.

A Fresh and Modern Identity Built In-House

Allison’s Brand and Engagement Strategy Team led the new brand identity, using its approach to research, strategy and branding for clients called V.I.T.A.L, which is a framework that helps companies understand and express a brand’s humanity (and therefore build engagement). The new brand features a sleek and modern logo that signifies the agency's evolution and commitment to innovation. The cutout in the I represent the agency’s vision of always moving forward with innovation and a commitment to excellence. The name change to "Allison" showcases a more inclusive and contemporary identity, while paying homage to the agency's founders and their values. The removal of "+Partners" reflects the team-oriented approach Allison has always been known for, emphasizing the agency's focus on inclusion, unity and diversity.

Forward-Looking Vision

With the rebrand, Allison sets its sights on its evolution to a fully integrated marketing and communications consultancy. Its Marketing Innovation Team offers integrated marketing, brand engagement strategies, performance marketing, creative, Storytelling Studio, and research and analytics functions, while its Allison Advisory team helps the C-suite accelerate growth by finding and optimizing the intersection of business goals, customer needs, regulatory environments and employee experience. The agency plans to bolster its creative capabilities, achieve rapid growth through targeted acquisitions, and continue to expand its service offerings beyond its PR roots driving innovation through a deep expertise in data and technology.

Brand Manifesto, Mission, Vision, and Purpose

The new brand manifesto, Always Forward, speaks to the agency's dedication to agility, innovation and forward momentum. The mission underscores that it's all about the work—unlocking insights, inspiring innovation and building meaningful connections. The vision and purpose highlight Allison's commitment to a limitless environment where everyone can build, create and grow, while using creativity to drive positive change and business success.

Agency Solutions

At the heart of the rebrand is a profound shift towards enhanced client offerings. Every solution is thoughtfully crafted to address the unique challenges our clients face in today's ever-changing global marketplace. By immersing ourselves in our clients' issues, Allison transcends the boundaries of conventional marketing, emerging as problem solvers and trusted partners. With this new approach, Allison emphasizes its ability to drive awareness and demand, increase cultural relevance, build and protect reputations, transform brands, and elevate business performance for clients across the globe. The solutions are not just services; they are pathways to success, strategies to create change and blueprints for navigating the dynamic marketing landscape.

With this rebrand, Allison is poised to embark on an exciting new chapter, while respecting the legacy of growth that has made it one of the greatest success stories in the industry over the past 22 years, showcasing its evolution, innovation and commitment to always move forward. The new brand identity captures the agency's spirit and dedication, ensuring it remains at the forefront of the industry for years to come.

About Allison

Allison is a global integrated marketing and communications consultancy, dedicated to driving growth, innovation, and positive change for clients, colleagues, and communities. With a diverse range of expertise and a forward-looking mindset, Allison delivers game-changing results that make a lasting impact. Allison is owned by Stagwell (NASDAQ: STGW), one of the fastest growing and most influential marketing and communications networks in the world. Agency partners leverage Stagwell’s technology, data analytics, insights and strategic consulting solutions to drive measurable results and optimize return on marketing investment for more than 1,700 clients worldwide. Learn more at www.allisonworldwide.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For media inquiries:

Shanna Brown
Shanna.Brown@allisonworldwide.com
646.428.6837

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye